Shots:

• Genentech & Convelo collaborate to discover and develop remyelination therapies for patients with neurological disorders including multiple sclerosis
• Convelo to receive up front and research support from Genentech. Genentech to retain an exclusive option to acquire Convelo in all-stock transaction for additional payment and downstream milestones
• Remyelinating therapies are involved in unlocking the regenerative capacity of the CNS by generating the protective myelin coating around nerve cells for neurological diseases like MS- pediatric leukodystrophies- traumatic injury and Alzheimer’s

Click here to read full press release/ article | Ref: Convelo | Image: Convelo